Twenty patients with chronic hepatitis c were investigated during the treatment with interferon to explore the changes of antibodies to HCV (anti-RCV). Anti-HCV was tested with recombinant immunoblot assay (RIBA) by u...Twenty patients with chronic hepatitis c were investigated during the treatment with interferon to explore the changes of antibodies to HCV (anti-RCV). Anti-HCV was tested with recombinant immunoblot assay (RIBA) by using three antigens (C22, C33c, and C100-3) encoded by different regions of HCV genome. The changes of individual anti-HCV and ALT were compared with the change of HCV RNA. The results showed that persistent disappearance of serum HCV RNA was closely related to the changes of anti-C33c (P<0. 01) and anti-C100-3 (P<0. 005), but there was no relation between persistent ALT normality and HCV viremia clearance (P<0. 05). In conclusion, monitoring anti-C33c and anti-C100-3 could indicate the changes or HCV viremia. The normalization of ALT after interferon treatment did not indicate disappearance of HCV viremia.展开更多
The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control gr...The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.展开更多
文摘Twenty patients with chronic hepatitis c were investigated during the treatment with interferon to explore the changes of antibodies to HCV (anti-RCV). Anti-HCV was tested with recombinant immunoblot assay (RIBA) by using three antigens (C22, C33c, and C100-3) encoded by different regions of HCV genome. The changes of individual anti-HCV and ALT were compared with the change of HCV RNA. The results showed that persistent disappearance of serum HCV RNA was closely related to the changes of anti-C33c (P<0. 01) and anti-C100-3 (P<0. 005), but there was no relation between persistent ALT normality and HCV viremia clearance (P<0. 05). In conclusion, monitoring anti-C33c and anti-C100-3 could indicate the changes or HCV viremia. The normalization of ALT after interferon treatment did not indicate disappearance of HCV viremia.
文摘The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.
